Vanda Pharmaceuticals Inc(VNDA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.62 | Insider Own | 5.4% | Shs Outstand | 60.5M | Perf Week | - |
| Market Cap | 0.24B | Forward P/E | - | EPS next Y | 72.65% | Insider Trans | - | Shs Float | 57.2M | Perf Month | -17.52% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | -0.37 | Inst Own | 86.49% | Short Float | 14.53% | Perf Quarter | -20.59% |
| Income | -0.27B | P/S | 1.07 | EPS this Y | 29.41% | Inst Trans | 2.19% | Short Ratio | 8.3 | Perf Half Y | -42.96% |
| Sales | 0.23B | P/B | 1.11 | EPS next 5Y | 47.86% | ROA | -55.89% | Short Interest | 8.31M | Perf YTD | -54.08% |
| Book/sh | 3.64 | P/C | 1.74 | EPS past 3/5Y | - | ROE | -82.55% | 52W High | -59.26% ($9.94) | Perf Year | -25.14% |
| Cash/sh | 2.32 | P/FCF | - | Sales past 3/5Y | -5.29% -2.73% | ROIC | -126.56% | 52W Low | 6.86% ($3.79) | Perf 3Y | -2.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -222.5% | Gross Margin | 95.9% | Volatility(W/M) | 8.16% 5.32% | Perf 5Y | -76.34% |
| Dividend TTM | - | EV/Sales | 0.53 | Sales Y/Y TTM | 8.11% | Oper. Margin | -77.59% | ATR (14) | 0.24 | Perf 10Y | -72.82% |
| Dividend Ex-Date | - | Quick Ratio | 1.53 | EPS Q/Q | 2.38% | Profit Margin | -119.87% | RSI (14) | 33.52 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.54 | Sales Q/Q | 24.1% | SMA20 | -4.74% ($4.25) | Beta | 0.7 | Target Price | $11.5 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/10/28 | SMA50 | -16.01% ($4.82) | Rel Volume | 2.7 | Prev Close | $4 |
| Employees | 533 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 45.75% 0.89% | SMA200 | -35.03% ($6.23) | Avg Volume(3M) | 1.00M | Price | $4.05 |
| IPO | 2006/4/12 | Option/Short | Yes/Yes | Trades | 10538 | Volume | 2,704,250 | Change | 1.25% |
💊 This US biotech company focuses on the central nervous system and psychiatric disorders. It markets commercialized products such as Hetlioz (HETLIOZ), a treatment for non-24-hour sleep-wake disorder, and Fanapt, a treatment for schizophrenia, and its stock price volatility is largely driven by FDA approval timelines for its pipeline of drug candidates.
Over the past 1 year, on the lower side
59% below its 1-year high.
Traded more than usual. That is 270% of its average volume.
VNDA has a sound balance sheet but weak earning power
Of every $100 in sales, $77.59 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +29.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $107. Peers typically go for $1,089. Compared with its own 2-year average, it is 211% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -76.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 86.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #287 of 594 in the industry
Based on market cap of $245M.
EVMN#285 Evommune Inc $247M PER - 
ELDN#286 Eledon Pharmaceuticals Inc $247M PER - VNDA#287 Vanda Pharmaceuticals Inc $245M PER - 
CAMP#288 CAMP4 Therapeutics Corp $245M PER - 
ACIU#289 AC Immune SA $241M PER - 
FAQ
What kind of company is VNDA?
VNDA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VNDA?
The market cap of VNDA is approximately $245M, ranking 3,859 within its sector.
What is the 52-week high and low for VNDA?
VNDA has recorded a 52-week high of $9.94 and a low of $3.79.
